SCHEMBL1920403

SCHEMBL1920403

O=[C]c1cc2ccccc2c2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
RAD52 P43351 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
TRPM4 Q8TD43 1/20 0.46
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 4/20 0.46
HIF1A Q16665 2/20 0.46
CYP1B1 Q16678 2/20 0.46
HPRT1 P00492 3/20 0.44
TSHR P16473 2/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
CYP2A6 P11509 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PAX8 Q06710 1/20 0.41
GPR84 Q9NQS5 1/20 0.39
CYP1A2 P05177 3/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9410288 0.78 ALDH1A1 (0.38) POLBMAPTPKMRAD52TAAR1
SCHEMBL194524 0.78 HPRT1 (0.58) MAPTALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL11542686 0.78 CA1 (0.46) ALDH1A1HSD17B10HIF1ATSHRCYP2A6
SCHEMBL313567 0.77 TRPM4 (0.46) POLBMAPTPKMRAD52TAAR1
SCHEMBL31588629 0.77 NCOA3 (0.65) POLBMAPTPKMRAD52TAAR1
SCHEMBL17530125 0.77 TRPM4 (0.46) POLBMAPTPKMRAD52TAAR1
SCHEMBL151389 0.77 NCOA3 (0.65) POLBMAPTPKMRAD52TAAR1
SCHEMBL31587957 0.77 TRPM4 (0.46) POLBMAPTPKMRAD52TAAR1
SCHEMBL9098788 0.77 NQO2 (0.55) POLBMAPTPKMRAD52TAAR1
SCHEMBL21178065 0.77 CYP1A2 (0.55) POLBMAPTPKMRAD52TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813979-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2023-09-29 CN disclosed
CN-112839988-B Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2023-06-06 CN disclosed
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-12-23 US disclosed
EP-3858909-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-08-04 EP disclosed
CN-112839988-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2021-05-25 CN disclosed
US-20170355642-A1 MONO- AND BISALKYLENETRIALKOXYSILANE DISPERSANTS FOR HYDRAULIC BINDERS BASF SE (DE) 2017-12-14 US disclosed
EP-3209707-A1 MONO- AND BISALKYLENE TRIALKOXYSILANES AS DISPERSANTS FOR HYDRAULIC BINDERS BASF SE (DE) 2017-08-30 EP disclosed
US-8394974-B2 Process for producing optically active chromene oxide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-03-12 US disclosed
EP-1718629-B1 Benzopyran compounds useful for the treatment of arrhytmia NISSAN CHEMICAL IND LTD (JP) 2012-12-26 EP disclosed
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
WO-2002100410-A1 METHODS OF TREATING ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-12-19 WO disclosed
US-20020020832-A1 Photosensitive resin composition CIBA SPECIALTY CHEMICALS CORP. 2002-02-21 US disclosed
US-5753652-A Antiretroviral hydrazine derivatives NOVARTIS CORPORATION (US) 1998-05-19 US disclosed
EP-0521827-B1 Pharmacological active hydrazin derivatives and process for their preparation CIBA GEIGY AG (CH) 1996-09-25 EP disclosed
EP-0604368-B1 Anti retroviral hydrazine derivatives CIBA GEIGY AG (CH) 1996-09-18 EP disclosed
EP-0604368-A1 Anti retroviral hydrazine derivatives CIBA-GEIGY AG (CH) 1994-06-29 EP disclosed
EP-0521827-A1 Pharmacological active hydrazin derivatives and process for their preparation CIBA-GEIGY AG (CH) 1993-01-07 EP disclosed
US-4931591-A Novel 5-amino-4-hydroxyvaleryl derivatives CIBA-GEIGY CORPORATION (US) 1990-06-05 US disclosed
US-4727060-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1988-02-23 US disclosed
EP-0184550-A2 5-Amino-4-hydroxy valeryl amide derivatives CIBA-GEIGY AG (CH) 1986-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF NOC2L, RIF1, NAP1L1 POLB 1078/4885MAPT 1265/4885PKM 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.